Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience
ConclusionThe current study suggests that FOLFOXIRI ± bevacizumab therapy in real-world patients with mCRC is associated with a high rate of conversion from unresectable to resectable metastatic disease. Patients with metastasectomy had better survival.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Avastin | Canada Health | Cancer | Cancer & Oncology | Colorectal Cancer | Eloxatin | Gastroenterology | Liver | Rectal Cancers | Study | Toxicology | Urology & Nephrology